232 related articles for article (PubMed ID: 27679471)
1. Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study.
Vitale A; Emmi G; Lopalco G; Gentileschi S; Silvestri E; Fabiani C; Urban ML; Frediani B; Galeazzi M; Iannone F; Rigante D; Cantarini L
Clin Rheumatol; 2017 Feb; 36(2):451-455. PubMed ID: 27679471
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Vannozzi L; Lopalco G; Guerriero S; Orlando I; Franceschini R; Bacherini D; Cimino L; Soriano A; Frediani B; Galeazzi M; Iannone F; Tosi GM; Salvarani C; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):183-189. PubMed ID: 27853889
[TBL] [Abstract][Full Text] [Related]
3. Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study.
Fabiani C; Sota J; Vitale A; Rigante D; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Gentileschi S; Capozzoli M; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Br J Ophthalmol; 2018 May; 102(5):637-641. PubMed ID: 28844047
[TBL] [Abstract][Full Text] [Related]
4. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies.
Fabiani C; Sota J; Rigante D; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Bitossi A; Orlando I; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2018 Oct; 37(10):2805-2809. PubMed ID: 29766375
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement.
Emmi G; Vitale A; Silvestri E; Boddi M; Becatti M; Fiorillo C; Fabiani C; Frediani B; Emmi L; Di Scala G; Goldoni M; Bettiol A; Vaglio A; Cantarini L; Prisco D
Arthritis Rheumatol; 2018 Sep; 70(9):1500-1507. PubMed ID: 29676522
[TBL] [Abstract][Full Text] [Related]
7. Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.
Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Sota J; Vannozzi L; di Scala G; Guerriero S; Orlando I; Franceschini R; Capozzoli M; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2018 Jun; 37(6):1715-1720. PubMed ID: 29671190
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behçet's uveitis with vasculitis.
Yang S; Huang Z; Liu X; Li H; Xie L; Chen X; Wen F; Liang D; Su W
Int Immunopharmacol; 2021 Apr; 93():107430. PubMed ID: 33581500
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
[TBL] [Abstract][Full Text] [Related]
10. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
[TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet's disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study.
Lee SB; Hong HS; Lee CK; Lee BI; Kim S; Koh SJ; Yu H; Park JB; Hwang SW; Ye BD; Yang SK; Park SH;
Korean J Intern Med; 2023 Sep; 38(5):661-671. PubMed ID: 37491721
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients.
Desbois AC; Biard L; Addimanda O; Lambert M; Hachulla E; Launay D; Ackermann F; Pérard L; Hot A; Maurier F; Mausservey C; Bernard F; Noel N; Alric L; Mirault T; Cohen F; Boussouar S; Resche-Rigon M; Cacoub P; Saadoun D
Clin Immunol; 2018 Dec; 197():54-59. PubMed ID: 30125675
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome.
Silvestri E; Bitossi A; Bettiol A; Emmi G; Urban ML; Mattioli I; Di Scala G; Bacherini D; Lopalco G; Venerito V; Iannone F; Vitale A; Tosi GM; Rizzo S; Fabiani C; Cantarini L; Virgili G; Vannozzi L; Prisco D
Inflammopharmacology; 2020 Jun; 28(3):711-718. PubMed ID: 32157555
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature.
Aksoy A; Yazici A; Omma A; Cefle A; Onen F; Tasdemir U; Ergun T; Direskeneli H; Alibaz-Oner F
Int J Rheum Dis; 2020 Feb; 23(2):256-261. PubMed ID: 31976619
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of TNF inhibitors in patients with Behçet's disease: Retrospective study from eastern Turkey.
Bektaş M; Özer MD; Oğuz E
Clin Immunol; 2024 Jul; 264():110239. PubMed ID: 38734038
[TBL] [Abstract][Full Text] [Related]
18. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients.
Barroso-García N; Atienza-Mateo B; Ferraz-Amaro I; Prieto-Peña D; Beltrán E; Adán A; Hernández-Garfella M; Martínez-Costa L; Cordero-Coma M; Díaz-Llopis M; Herreras JM; Maíz-Alonso O; Torre-Salaberri I; De Vicente-Delmás A; Díaz-Valle D; Atanes-Sandoval A; Francisco F; Insua S; Sánchez J; Almodóvar-González R; Jiménez-Sosa A; Ruiz-Moreno O; Gandía-Martínez M; Nolla JM; Calvo-Río V; Castañeda S; González-Gay MA; Blanco R
Semin Arthritis Rheum; 2023 Feb; 58():152153. PubMed ID: 36549244
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies.
Verboom DM; van der Houwen TB; Kappen JH; van Daele PLA; Dik WA; Schreurs MWJ; van Hagen PM; van Laar JAM
Clin Exp Rheumatol; 2019; 37 Suppl 121(6):43-47. PubMed ID: 30873952
[TBL] [Abstract][Full Text] [Related]
20. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis.
Fabiani C; Vitale A; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Capozzoli M; Fusco F; Rana F; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
Clin Rheumatol; 2019 Jan; 38(1):63-70. PubMed ID: 29611087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
